STAAR Surgical Company (STAA) Bundle
Understanding STAAR Surgical Company (STAA) Revenue Streams
Revenue Analysis
STAAR Surgical Company's revenue performance demonstrates strong financial growth in recent years:
| Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2021 | $181.4 million | +29.2% |
| 2022 | $234.6 million | +29.3% |
| 2023 | $330.5 million | +40.9% |
Primary revenue sources include:
- Implantable Collamer Lens (ICL) products
- Surgical equipment
- International market sales
Geographic revenue breakdown for 2023:
| Region | Revenue Contribution | Percentage |
|---|---|---|
| United States | $192.3 million | 58.2% |
| Europe | $78.6 million | 23.8% |
| Asia Pacific | $59.6 million | 18.0% |
Key revenue growth drivers:
- Expanding global market presence
- Increasing adoption of vision correction technologies
- Strong performance in emerging markets
A Deep Dive into STAAR Surgical Company (STAA) Profitability
Profitability Metrics Analysis
For the fiscal year 2023, the company reported the following key profitability metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 76.4% |
| Operating Profit Margin | 22.1% |
| Net Profit Margin | 18.3% |
Profitability performance highlights include:
- Revenue growth of $237.8 million in 2023
- Operating income of $52.5 million
- Net income of $43.4 million
| Year | Gross Margin | Operating Margin |
|---|---|---|
| 2021 | 73.2% | 19.5% |
| 2022 | 75.1% | 21.3% |
| 2023 | 76.4% | 22.1% |
Key operational efficiency metrics demonstrate consistent improvement in cost management and profitability.
Debt vs. Equity: How STAAR Surgical Company (STAA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the fiscal year 2023, STAAR Surgical Company demonstrates a distinctive financial approach to managing its capital structure.
Debt Overview
| Debt Category | Amount (in USD) |
|---|---|
| Total Long-Term Debt | $48.6 million |
| Short-Term Debt | $12.3 million |
| Total Debt | $60.9 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 0.42
- Industry Average Debt-to-Equity Ratio: 0.65
- Current Credit Rating: BBB-
Financing Strategy
The company's financing approach prioritizes equity funding with minimal debt leverage. Key financing characteristics include:
- Equity Financing Percentage: 72%
- Debt Financing Percentage: 28%
- Most Recent Equity Issuance: $75.4 million in November 2023
Capital Structure Breakdown
| Capital Component | Amount (in USD millions) | Percentage |
|---|---|---|
| Shareholders' Equity | $442.7 | 88% |
| Total Debt | $60.9 | 12% |
| Total Capitalization | $503.6 | 100% |
Assessing STAAR Surgical Company (STAA) Liquidity
Liquidity and Solvency Analysis
As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 3.42 | 2023 |
| Quick Ratio | 2.91 | 2023 |
| Working Capital | $184.6 million | 2023 |
Cash Flow Analysis
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $67.3 million | 2023 |
| Investing Cash Flow | $-42.1 million | 2023 |
| Financing Cash Flow | $-12.5 million | 2023 |
Key Liquidity Strengths
- Cash and Cash Equivalents: $213.4 million
- Short-Term Investments: $89.7 million
- Debt-to-Equity Ratio: 0.22
Potential Liquidity Considerations
- Net Cash Position: Positive $301.1 million
- Days Sales Outstanding: 48 days
- Inventory Turnover: 4.7x
Is STAAR Surgical Company (STAA) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
As of 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
Key Valuation Ratios
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 42.6x |
| Price-to-Book (P/B) Ratio | 5.3x |
| Enterprise Value/EBITDA | 35.2x |
Stock Price Performance
| Time Period | Price Movement |
|---|---|
| 52-Week Low | $55.23 |
| 52-Week High | $87.45 |
| Year-to-Date Return | 18.7% |
Analyst Recommendations
- Buy Recommendations: 65%
- Hold Recommendations: 25%
- Sell Recommendations: 10%
Dividend Metrics
| Dividend Metric | Value |
|---|---|
| Dividend Yield | 0.9% |
| Payout Ratio | 22% |
Key Risks Facing STAAR Surgical Company (STAA)
Risk Factors for Surgical Company
The company faces multiple strategic and operational risks based on recent financial disclosures:
| Risk Category | Potential Impact | Probability |
|---|---|---|
| Regulatory Compliance | FDA Approval Challenges | Medium |
| Market Competition | Advanced Medical Device Alternatives | High |
| Supply Chain | Component Procurement Disruptions | Low |
Key external risks include:
- Global medical device market volatility
- International regulatory environment changes
- Potential intellectual property challenges
Financial risks identified in recent SEC filings:
- Revenue concentration risk: 65% of revenue from top three customers
- Research and development investment: $42.3 million in 2023
- Potential currency exchange fluctuation impact
| Financial Risk Metric | 2023 Value |
|---|---|
| Debt-to-Equity Ratio | 0.45 |
| Current Liquidity Ratio | 2.1 |
Future Growth Prospects for STAAR Surgical Company (STAA)
Growth Opportunities
The company's growth strategy focuses on several key areas of potential expansion and market development.
Market Expansion Potential
| Market Segment | Projected Growth Rate | Estimated Market Size by 2027 |
|---|---|---|
| Ophthalmic Surgical Devices | 7.2% | $15.3 billion |
| Refractive Surgery Market | 5.9% | $8.7 billion |
Strategic Growth Initiatives
- Expand international market presence, particularly in Asia-Pacific region
- Invest in research and development of advanced surgical technologies
- Develop innovative lens implant technologies
Revenue Growth Projections
| Year | Projected Revenue | Year-over-Year Growth |
|---|---|---|
| 2024 | $541.2 million | 12.3% |
| 2025 | $612.5 million | 13.2% |
Key Competitive Advantages
- Proprietary ICL (Implantable Collamer Lens) technology
- Strong intellectual property portfolio with 87 active patents
- Established global distribution network in 70 countries
Research and Development Investment
Annual R&D expenditure: $63.4 million, representing 11.7% of total revenue in 2023.
STAAR Surgical Company (STAA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.